Beranda › Leukemia Biphenotypic Akut › Oklahoma › Oklahoma City
Uji klinis Leukemia Biphenotypic Akut di Oklahoma City, OK
3 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Baldwin Park, CA6 studi
- Aurora, CO6 studi
- Dallas, TX6 studi
- Philadelphia, PA6 studi
Studi lain di Oklahoma City
- Kanker Paru Non-Sel Kecil28 studi
- Kanker Ovarium28 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal22 studi
- Kanker Prostat21 studi
- Kanker Paru19 studi
- Kanker Payudara17 studi
- Kanker Metastatik16 studi
- Kanker (semua jenis)14 studi
- Leukemia Mieloid Akut14 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Kanker Kandung Kemih11 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.